Xeljanz (tofacitinib) can affect patients with kidney conditions. The recommended dosage of Xeljanz should be reduced to 5 mg once daily in patients with severe renal impairment (creatinine clearance <30 mL/min). Xeljanz can also cause liver damage by altering its enzyme levels, as shown in clinical trials. For patients with pre-existing liver conditions, close monitoring during treatment with Xeljanz is essential. Symptoms of liver damage may include stomach pain, yellowing of the eyes or skin, and dark urine.
It’s important to discuss the potential risks and benefits of Xeljanz treatment with your healthcare provider, especially if you have underlying kidney or liver issues.
